Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesOther financing activitiesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Insight Molecular Diagnostics (IMDX) Asset Writedowns and Impairment: 2020-2024

Historic Asset Writedowns and Impairment for Insight Molecular Diagnostics (IMDX) over the last 1 years, with Dec 2024 value amounting to $36.9 million.

  • Insight Molecular Diagnostics' Asset Writedowns and Impairment rose 922600.00% to $36.9 million in Q4 2024 from the same period last year, while for Dec 2024 it was $43.7 million, marking a year-over-year increase of 515.67%. This contributed to the annual value of $41.9 million for FY2024, which is 520.10% up from last year.
  • Per Insight Molecular Diagnostics' latest filing, its Asset Writedowns and Impairment stood at $36.9 million for Q4 2024, which was up 922,600.00% from -$4,000 recorded in Q4 2023.
  • Insight Molecular Diagnostics' Asset Writedowns and Impairment's 5-year high stood at $36.9 million during Q4 2024, with a 5-year trough of -$334,000 in Q3 2020.
  • Moreover, its 2-year median value for Asset Writedowns and Impairment was $3.4 million (2023), whereas its average is $10.9 million.
  • Data for Insight Molecular Diagnostics' Asset Writedowns and Impairment shows a peak YoY surged of 922,600.00% (in 2024) over the last 5 years.
  • Over the past 3 years, Insight Molecular Diagnostics' Asset Writedowns and Impairment (Quarterly) stood at $334,000 in 2020, then reached -$4,000 in 2023, then surged by 922,600.00% to $36.9 million in 2024.
  • Its Asset Writedowns and Impairment stands at $36.9 million for Q4 2024, versus -$4,000 for Q4 2023 and $1.8 million for Q3 2023.